Cognitive-Frailty Gait Biomechanics for Early Dementia Detection
ConditionMild Cognitive Impairment (MCI)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorUniversiti Sains Malaysia
About this trial
The purpose of this study is to better understand how physical characteristics, walking patterns, and a blood-based brain health marker differ between older adults with dementia and healthy older adults.
Dementia is often associated with changes in physical health and movement, but these changes are not fully understood. This study asks whether people with dementia show differences in body composition, walking ability, and levels of brain-derived neurotrophic factor (BDNF), a protein involved in brain function, compared with individuals without dementia.
To answer this question, participants will complete a single assessment session that includes basic physical measurements, an assessment of walking while moving at a comfortable pace, and a small blood sample collection. The information collected will be used to compare the two groups and explore possible relationships between physical function, walking patterns, and BDNF levels.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Older adults aged 50 years and above
Able to ambulate independently without the use of walking aids
Must be able to understand instructions, communicate effectively
Free from any acute or unstable medical conditions at the time of assessment.
Disqualifiers
Present with any diagnosed neurological disorder such as stroke or Parkinson's disease
History of psychiatric illness, including major depressive disorder.
Individuals with uncontrolled cardiovascular, metabolic, or endocrine conditions
Have significant visual, auditory, or musculoskeletal impairments that may influence gait performance
Trial population
USM memory clinic
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
60 Participants
are grouped into 2 trial groupsGroup A: MCI group
Group B: Healthy control group
Trial outcomes
Primary outcomes
1
Gait speed during normal walking
Average gait speed measured during normal walking using motion capture analysis. Unit of Measure: Meters per second (m/s)
Time frame
At baseline (single assessment)2
Stride length during normal walking
Mean stride length measured during normal walking using motion capture analysis. Unit of Measure: Meters (m)
Time frame
At baseline3
Cadence during normal walking
Cadence measured during normal walking using motion capture analysis. Unit of Measure: Steps per minute (steps/min)
Time frame
At baseline (single assessment)4
Cognitive function assessed by the Montreal Cognitive Assessment (MoCA)
Global cognitive function measured using the Montreal Cognitive Assessment (MoCA), a standardized cognitive screening tool assessing multiple cognitive domains. Unit of Measure: Score on a scale Scale Description: Montreal Cognitive Assessment (MoCA) total score ranges from 0 to 30, with higher scores indicating better cognitive function.
Time frame
At baseline (single assessment)Secondary outcomes
1
Handgrip strength
Maximum handgrip strength measured using a handheld dynamometer. Unit of Measure: Kilograms (kg)
Time frame
At baseline2
Serum brain-derived neurotrophic factor (BDNF) concentration
Serum brain-derived neurotrophic factor (BDNF) concentration measured from blood samples. Unit of Measure: ng/mL
Time frame
At baseline3
Functional mobility assessed by the Timed Up and Go test
Functional mobility measured using the Timed Up and Go (TUG) test, which assesses the time required to stand up from a chair, walk 3 meters, turn, return, and sit down. Unit of Measure: Seconds (s) Directionality: Lower values indicate better functional mobility.
Time frame
At baseline (single assessment)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: